Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Merlin Assay

Skyline Dx
CE Marked
Merlin Assay, identifies melanoma (skin cancer) patients for whom postponing sentinel lymph node biopsy (SLNB) surgery would be at minimal risk, allowing physicians to better triage care and allocate resources. The Merlin assay uses the CP-GEP model, a powerful algorithm that calculates the risk of metastasis in a patient's sentinel lymph nodes. The model is able to calculate risk on an individual basis through a combination analysis of 8 genes from the patient's primary tumor, the tumor thickness and the patient's age. The Merlin Assay is available as Laboratory Developed Test in CAP/CLIA lab in San Diego.